Q-omics provides the consensus-scored BLCAP profile across patient tissues and cancer cell-line models. BLCAP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BLCAP is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, BLCAP RNA expression shows 19,853 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where BLCAP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLCAP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLCAP survival associations across molecular data types. BLCAP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLCAP RNA expression–survival associations across cancer types. High BLCAP expression shows unfavorable associations in HNSC, OV and ACC, but favorable associations in CESC, BRCA and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BLCAP RNA expression.
This table summarizes BLCAP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BLCAP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLCAP shows lower tumor expression in KIRC and BRCA and higher tumor expression in HNSC, COAD, LUSC and STAD. The HNSC box plot shows higher BLCAP RNA expression in tumor versus normal tissue (log2 FC = +0.635, t-test p < 0.001).
This table shows molecular features associated with BLCAP in patient tissues and cancer cell lines. In patient samples, BLCAP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, BLCAP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
